Today: 30 June 2026
Browse Category

NASDAQ:RZLT 11 December 2025 - 24 December 2025

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. is still in the spotlight on December 24, 2025, after a brutal mid-December selloff tied to its pivotal clinical trial news—and a wave of follow-on analyst downgrades, price-target resets, and investor-law-firm investigations. As of the latest available pricing around $2.42 per share, the stock is off its post-trial lows but remains dramatically below pre-readout levels, leaving investors weighing a simple question with complicated consequences: was sunRIZE a fatal blow, or a detour that shifts the story toward Rezolute’s next late-stage program? MarketBeat+1 Below is a complete, publication-ready breakdown of the current RZLT stock news, forecasts, and analyses available as of 24.12.2025, focused on what moved the stock, what Wall Street is saying now, and what milestones matter next.
24 December 2025
··
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update on Friday, December 12, 2025, Rezolute shares are trading around $1.40, down roughly $9.55 versus the prior close—about an 87% one-day collapse that has reset expectations across Wall Street. This article covers what happened, why it matters, where sell-side forecasts now stand, and what catalysts could still move Rezolute stock next.
12 December 2025
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

U.S. stocks closed mixed on Thursday, December 11, 2025, as a historic surge in the Dow clashed with a sharp tech sell‑off led by Oracle and a wave of brutal collapses in thinly traded micro‑caps. By the closing bell, the Dow Jones Industrial Average was up roughly 1.3–1.4% and at a record high, while the S&P 500 edged about 0.1–0.2% higher. The Nasdaq Composite, however, slipped around 0.3–0.4%, dragged down by AI‑linked growth stocks.TradingView+2StockAnalysis+2
11 December 2025
····
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

As Wall Street digests a fresh Federal Reserve rate cut and growing worries about an AI spending bubble, today’s U.S. stock tape is dominated by dramatic downside moves. From Oracle’s double‑digit plunge to biotech blow‑ups and reverse‑split micro‑caps, December 11, 2025 is one of the ugliest “losers lists” investors have seen this year. Below is a news‑driven breakdown of what’s happening, why these stocks are sinking, and what the day’s biggest losers say about the broader U.S. market.
11 December 2025
····

Stock Market Today

  • BCE, Telus weigh AI spending against TSX dividends
    June 29, 2026, 9:24 PM EDT. BCE and Telus are putting more money into AI infrastructure, a move that is hitting dividends for both TSX telecoms. BCE committed $1.3 billion to a new AI data centre, looking for $500 million in annual revenue and $250 million free cash flow from it, but said it would cut its 2025 dividend by 56%. The company is now focusing on deleveraging and keeping its payout manageable over chasing dividend growth. Telus is targeting over $66 billion for AI projects in five years, which could push back its aim for 10% free cash flow growth and cutting debt by 2028. Telus has kept up dividends but hasn't seen its stock rally like BCE. Both are facing tight dividend growth as they shift spending to AI and focus on the balance sheet.
Go toTop